Medicare expansion of stem cell transplant coverage is a win
But do other myeloma treatments' availability make the change less meaningful?
Written by |
The U.S. Centers for Medicare and Medicaid Services (CMS) has expanded eligibility for an autologous stem cell transplant (ASCT) that will add the International Staging System (ISS) as a criterion, even for Stage 1 multiple myeloma patients.
The move is a change from an earlier proposal that would have left Stage 1 patients still reliant on the 1970s-era Durie Salmon Staging System to decide whether to cover a stem cell transplant.
I first wrote about the possible change in August. Durie Salmon uses blood and urine tests along with imaging to stage a patient. The ISS, developed in 2005, and the 2015 Revised International Staging System (R-ISS) use blood tests.
CMS considers the ISS and R-ISS better at predicting progression-free and overall survival for ASCT patients, and wrote a proposed new rule for ASCT coverage, then put out a call for public comment.
The problem with the proposal
The proposed new criteria did not include ISS Stage 1 patients at first. That worried myeloma doctors and patients who filed comments on CMS’ website, and referred to research that showed that Stage 1 patients benefited the most from stem cell transplants. Others said treatment options should not be taken away from patients.
Overall, CMS received 172 comments, and the agency said most “suggested that CMS cover ASCT for all [multiple myeloma] patients with active disease or expand to include all ISS stages.”
On Oct. 28, it issued a decision that read that ASCT is now covered for multiple myeloma patients with active disease who are in “any stage using the International Staging System and its revisions.” The decision does not eliminate Durie-Salmon. Patients at Stages II or III in that system will still be covered.
But why still bother with stem cell transplant when there so many other treatments available now? Debates about the future of stem cell transplants were heard at just about every myeloma event I attended this year, with some predicting they will no longer be done in just a few years thanks to immunotherapies. It’s unlikely, however, that they will be replaced as standard of care until trials provide definitive proof that other treatments are superior.
It will be a good day when patients won’t have to get their immune and digestive systems firebombed by heavy doses of melphalan. But when I think about eliminating transplants altogether, I am reminded of a newscast I produced in 1991 during the Gulf War that saw the U.S. invade Iraq. In the middle of our reporting, our brand-new computer system crashed, so we hauled out the old typewriters and did the news.
Call me old-fashioned, but I like having lots of tools in the toolbox, even if some rarely — or never — get used.
Note: Rare Cancer News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Rare Cancer News or its parent company, Bionews, and are intended to spark discussion about issues pertaining to rare cancer.
Leave a comment
Fill in the required fields to post. Your email address will not be published.